• Tilray Medical secured INFARMED clearance for on-site microbiological and chemical/physical quality testing at its EU-GMP Cantanhede facility.
• Move brings critical batch-release testing in-house, speeding product release across regulated medical cannabis markets.
• Shift reduces reliance on third-party labs, lowering release costs and shortening timelines from harvest to sale.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tilray Brands Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610130700OMX_____CNEWS_EN_GNW9844214_en) on October 13, 2026, and is solely responsible for the information contained therein.